Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETIC trial
2011-004139-29Phase 3Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Fibrinogen human, balfaxar, Factor XIII (human) and fresh-frozen plasma in trauma-induced coagulopathy (TIC) and Major trauma (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Occurrence of multi-organ failure. Started Nov 2011; status: terminated.
02
Drugs
Fibrinogen humanbalfaxarFactor XIII (human)fresh-frozen plasma
03
Conditions
trauma-induced coagulopathy (TIC)Major trauma
Beyond the preview
Go deeper on 2011-004139-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004139-29.